Literature DB >> 12228260

Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children.

Qibo Zhang1, Sharon Choo, Adam Finn.   

Abstract

Studies of mice suggest that pneumococcal proteins, including PspA, pneumolysin, PsaA, and CbpA, are promising vaccine candidates. To determine whether these proteins are good mucosal immunogens in humans, adenoidal lymphocytes from 20 children who had adenoidectomies were isolated and tested by ELISpot for antigen-specific antibody-secreting cells (ASCs). Cells were also cultured for 7 days in the presence of a concentrated culture supernatant (CCS) from a type 14 strain of pneumococcus which contained secreted pneumococcal proteins, including PspA, pneumolysin, PsaA, and CbpA, and then tested by ELISpot. ELISpot assays done on freshly isolated cells detected ASCs to all four antigens in most children studied. However, there were differences both between antigens and between isotypes. The densities of immunoglobulin G (IgG) ASCs against both PsaA and CbpA were significantly higher than those of ASCs for PspA and PdB (pneumolysin toxoid B) (P < 0.001). For all antigens, the numbers of IgA ASCs tended to be lower than those of both IgG and IgM ASCs. The numbers of anti-CbpA and -PsaA IgA ASCs were higher than those of anti-PdB IgA ASCs (P < 0.01). Concentrations of IgA antibodies to PspA and PsaA in saliva correlated with the numbers of IgA ASCs to PspA and PsaA in freshly isolated adenoidal cells, but no such correlation was found between salivary IgG antibody concentrations and IgG ASCs to the four antigens in adenoidal cells. In cultured cells, anti-PspA, -PsaA, and -CbpA IgG ASCs proliferated significantly, but only two of eight samples showed >2-fold increases in anti-CbpA and -PspA IgA ASCs after CCS stimulation. The results suggest that CbpA, PsaA, and PspA may be good upper respiratory mucosal antigens in children. Adenoids may be important inductive sites for memory IgG responses and important sources of salivary IgA. Some protein antigens may also prime for mucosal IgA memory. These data support the effort to explore mucosal immunization against pneumococcal infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228260      PMCID: PMC128328          DOI: 10.1128/IAI.70.10.5363-5369.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Salivary antibodies following parenteral immunization of infants with a meningococcal serogroup A and C conjugated vaccine.

Authors:  R Borrow; A J Fox; K Cartwright; N T Begg; D M Jones
Journal:  Epidemiol Infect       Date:  1999-10       Impact factor: 2.451

2.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Confirmation of psaA in all 90 serotypes of Streptococcus pneumoniae by PCR and potential of this assay for identification and diagnosis.

Authors:  K E Morrison; D Lake; J Crook; G M Carlone; E Ades; R Facklam; J S Sampson
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid.

Authors:  M Korkeila; H Lehtonen; H Ahman; O Leroy; J Eskola; H Käyhty
Journal:  Vaccine       Date:  2000-01-18       Impact factor: 3.641

5.  Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.

Authors:  C Czerkinsky; M W Russell; N Lycke; M Lindblad; J Holmgren
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

6.  Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.

Authors:  M J Crain; W D Waltman; J S Turner; J Yother; D F Talkington; L S McDaniel; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

7.  Human antibodies to pneumococcal surface protein A in health and disease.

Authors:  A Virolainen; W Russell; M J Crain; S Rapola; H Käyhty; D E Briles
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

8.  Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae.

Authors:  W D Waltman; L S McDaniel; B M Gray; D E Briles
Journal:  Microb Pathog       Date:  1990-01       Impact factor: 3.738

Review 9.  Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.

Authors:  N A Williams; T R Hirst; T O Nashar
Journal:  Immunol Today       Date:  1999-02

10.  The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia.

Authors:  A Brooks-Walter; D E Briles; S K Hollingshead
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

View more
  25 in total

Review 1.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

2.  Immunization with pneumolysin protects against both retinal and global damage caused by Streptococcus pneumoniae endophthalmitis.

Authors:  Melissa E Sanders; Erin W Norcross; Quincy C Moore; Jonathan Fratkin; Hilary Thompson; Mary E Marquart
Journal:  J Ocul Pharmacol Ther       Date:  2010-10-29       Impact factor: 2.671

3.  Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.

Authors:  F C Pimenta; E N Miyaji; A P M Arêas; M L S Oliveira; A L S S de Andrade; P L Ho; S K Hollingshead; L C C Leite
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 4.  Lipoproteins of bacterial pathogens.

Authors:  A Kovacs-Simon; R W Titball; S L Michell
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 5.  The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications.

Authors:  Michael J Carter; Ruth M Mitchell; Patrick M Meyer Sauteur; Dominic F Kelly; Johannes Trück
Journal:  Front Immunol       Date:  2017-06-01       Impact factor: 7.561

6.  Defective pneumococcal-specific Th1 responses in HIV-infected adults precedes a loss of control of pneumococcal colonization.

Authors:  Sarah J Glennie; Dominic Banda; Kate Gould; Jason Hinds; Arox Kamngona; Dean D B Everett; Neil A Williams; Robert S Heyderman
Journal:  Clin Infect Dis       Date:  2012-09-28       Impact factor: 9.079

7.  Active Immunization with Pneumolysin versus 23-Valent Polysaccharide Vaccine for Streptococcus pneumoniae Keratitis.

Authors:  Erin W Norcross; Melissa E Sanders; Quincy C Moore; Sidney D Taylor; Nathan A Tullos; Rhonda R Caston; Sherrina N Dixon; Moon H Nahm; Robert L Burton; Hilary Thompson; Larry S McDaniel; Mary E Marquart
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-29       Impact factor: 4.799

8.  Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization.

Authors:  Tera L McCool; Thomas R Cate; Elaine I Tuomanen; Peter Adrian; Tim J Mitchell; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage.

Authors:  Emma Holmlund; Beatriz Quiambao; Jukka Ollgren; Teija Jaakkola; Cécile Neyt; Jan Poolman; Hanna Nohynek; Helena Käyhty
Journal:  Clin Vaccine Immunol       Date:  2009-04-29

10.  Streptococcus pneumoniae nasopharyngeal colonization induces type I interferons and interferon-induced gene expression.

Authors:  Elizabeth A Joyce; Stephen J Popper; Stanley Falkow
Journal:  BMC Genomics       Date:  2009-08-27       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.